Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single center single arm clinical prospective study of neoantigen reactive T cells (NRTs) combined with PD-1 inhibitor in the treatment of Chinese patients with advanced refractory solid tumors

Next Previous
X
Search
Trial Profile

Single center single arm clinical prospective study of neoantigen reactive T cells (NRTs) combined with PD-1 inhibitor in the treatment of Chinese patients with advanced refractory solid tumors

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Neoantigens reactive T cell therapy (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Solid tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms NRT-01

    • Most Recent Events

    • 01 Aug 2017 Status changed from recruiting to suspended, according to an Incyte Corporation media release.
    • 02 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 04 May 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top